Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 19/20 | 1.00 |
| ▸ | BRD2 | P25440 | 8/20 | 1.00 |
| ▸ | BRD3 | Q15059 | 8/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 6/20 | 1.00 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.71 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.71 |
| ▸ | CCL2 | P13500 | 1/20 | 0.71 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.71 |
| ▸ | TACR1 | P25103 | 1/20 | 0.71 |
| ▸ | MAOB | P27338 | 1/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.71 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.71 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.71 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.71 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.71 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.71 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1904868 | 0.91 | BRD4 (0.83) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL18904291 | 0.90 | BRD4 (1.00) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL12168822 | 0.90 | BRD4 (0.82) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL1905504 | 0.89 | BRD4 (0.81) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL12098963 | 0.89 | BRD4 (0.84) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL12099000 | 0.88 | BRD4 (0.79) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL12099038 | 0.88 | BRD4 (0.78) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL1902557 | 0.87 | BRD4 (0.85) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL12098706 | 0.86 | BRD4 (0.83) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL12098937 | 0.86 | BRD4 (0.81) | BRD4BRD2BRD3CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3762004-B1 | TREATMENT OF TUMORS BY A COMBINATION OF AN ONCOLYTIC ADENOVIRUS AND A CDK4/6 INHIBITOR | KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIV MUENCHEN (DE) | 2023-09-13 | — | — | EP | disclosed |
| WO-2019183523-A1 | HETERO-BIFUNCTIONAL DEGRADER COMPOUNDS AND THEIR USE AS MODULATORS OF TARGETED UBIQUINATION (VHL) | GENENTECH, INC. (US) | 2019-09-26 | — | — | WO | disclosed |
| WO-2018024878-A1 | METHODS AND COMPOSITIONS FOR REDUCING PCSK9 EXPRESSION | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2018-02-08 | — | — | WO | disclosed |
| WO-2017091673-A2 | BIVALENT BROMODOMAIN INHIBTORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-06-01 | — | — | WO | disclosed |
| WO-2016105518-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-06-30 | — | — | WO | disclosed |
| EP-2496576-B1 | IMIDAZO[4,5-C]QUINOLINE DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-12-18 | — | — | EP | disclosed |
| US-8557984-B2 | Imidazo [4, 5-C] quinoline derivatives as bromodomain inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-10-15 | — | — | US | disclosed |
| US-8557984-B2 | Imidazo [4, 5-C] quinoline derivatives as bromodomain inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-10-15 | — | — | US | disclosed |
| US-20120232074-A1 | Imidazo [4, 5-C] Quinoline Derivatives As Bromodomain Inhibitors | GLAXOSMITHKLINE LLC | 2012-09-13 | — | — | US | disclosed |
| US-20120232074-A1 | Imidazo [4, 5-C] Quinoline Derivatives As Bromodomain Inhibitors | GLAXOSMITHKLINE LLC | 2012-09-13 | — | — | US | disclosed |
| EP-2496576-A1 | IMIDAZO [4, 5-C]QUINOLINE DERIVATES AS BROMODOMAIN INHIBITORS | GlaxoSmithKline LLC (US) | 2012-09-12 | — | — | EP | disclosed |
| WO-2011054846-A1 | IMIDAZO [4, 5-C] QUINOLINE DERIVATES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232074-A1 | Imidazo [4, 5-C] Quinoline Derivatives As Bromodomain Inhibitors | BRD4, BRD3, BRPF3 | BRD4 1/4885BRD2 5/4885BRD3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.